By Among premenopausal women with hormone receptor (HR)-positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on a genomic assay called Breast Cancer Index (BCI) had increased risk of distant recurrence, and those with low BCI benefited more from the addition of ovarian suppression therapy to endocrine therapy after 12 years of follow-up, according to data presented at the 2022 San Antonio Breast Cancer Symposium, held December 6-10, 2022.
Genomic assay may predict long-term prognosis in premenopausal patients with HR-positive early-stage breast cancer
Close up of chemical microscope and medical research equipment in scientific laboratory. Liquid examination tool with glass lens and blood samples in vacutainers on professional desk
Comments